These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25099086)

  • 1. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
    Groarke JD; Choueiri TK; Slosky D; Cheng S; Moslehi J
    Curr Treat Options Cardiovasc Med; 2014 Sep; 16(9):335. PubMed ID: 25099086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.
    Touyz RM; Herrmann SMS; Herrmann J
    J Am Soc Hypertens; 2018 Jun; 12(6):409-425. PubMed ID: 29703600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
    Touyz RM; Herrmann J
    NPJ Precis Oncol; 2018; 2():13. PubMed ID: 30202791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension in cancer patients treated with anti-angiogenic based regimens.
    Wasserstrum Y; Kornowski R; Raanani P; Leader A; Pasvolsky O; Iakobishvili Z
    Cardiooncology; 2015 Dec; 1(1):6. PubMed ID: 33530150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
    Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
    Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
    Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
    J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitor-Induced Hypertension.
    Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD
    Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
    Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL
    J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.
    Pucci G; Milan A; Paini A; Salvetti M; Cerasari A; Vaudo G
    Expert Opin Biol Ther; 2019 May; 19(5):433-442. PubMed ID: 30888868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
    Bair SM; Choueiri TK; Moslehi J
    Trends Cardiovasc Med; 2013 May; 23(4):104-13. PubMed ID: 23290365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
    Estrada CC; Maldonado A; Mallipattu SK
    J Am Soc Nephrol; 2019 Feb; 30(2):187-200. PubMed ID: 30642877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left Ventricular Dysfunction in Cancer Treatment: Is it Relevant?
    Kenigsberg B; Wellstein A; Barac A
    JACC Heart Fail; 2018 Feb; 6(2):87-95. PubMed ID: 29413379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Dysfunction and Chemotherapeutic Agents.
    Clasen SC; Wald JW
    Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
    Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
    Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.